Fluicell AB (publ) (FLUI.ST)
SEK 0.04
(0.5%)
SEK 0.04
(0.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.34 Million SEK | -70.6% |
| 2022 | 31.76 Million SEK | 17.73% |
| 2021 | 26.98 Million SEK | 8.66% |
| 2020 | 24.83 Million SEK | 24.54% |
| 2019 | 19.93 Million SEK | -23.24% |
| 2018 | 25.97 Million SEK | 125.17% |
| 2017 | 11.53 Million SEK | 315.68% |
| 2016 | 2.77 Million SEK | 62.66% |
| 2015 | 1.7 Million SEK | 2.04% |
| 2014 | 1.67 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 23.54 Million SEK | 152.09% |
| 2024 Q2 | 27.89 Million SEK | 18.49% |
| 2023 FY | 9.34 Million SEK | -70.6% |
| 2023 Q1 | 23.28 Million SEK | -26.71% |
| 2023 Q2 | 21.51 Million SEK | -7.57% |
| 2023 Q4 | 9.34 Million SEK | -32.64% |
| 2023 Q3 | 13.86 Million SEK | -35.57% |
| 2022 Q2 | 22.46 Million SEK | 5.13% |
| 2022 Q4 | 31.76 Million SEK | 77.94% |
| 2022 Q1 | 21.37 Million SEK | -20.79% |
| 2022 FY | 31.76 Million SEK | 17.73% |
| 2022 Q3 | 17.85 Million SEK | -20.55% |
| 2021 Q1 | 23.4 Million SEK | -5.75% |
| 2021 FY | 26.98 Million SEK | 8.66% |
| 2021 Q4 | 26.98 Million SEK | -21.37% |
| 2021 Q3 | 34.31 Million SEK | 101.37% |
| 2021 Q2 | 17.04 Million SEK | -27.19% |
| 2020 Q4 | 24.83 Million SEK | -1.39% |
| 2020 Q1 | 14.96 Million SEK | -24.93% |
| 2020 Q2 | 39.48 Million SEK | 163.82% |
| 2020 Q3 | 25.18 Million SEK | -36.23% |
| 2020 FY | 24.83 Million SEK | 24.54% |
| 2019 Q1 | 22.13 Million SEK | -14.77% |
| 2019 FY | 19.93 Million SEK | -23.24% |
| 2019 Q4 | 19.93 Million SEK | 50.87% |
| 2019 Q3 | 13.21 Million SEK | -24.13% |
| 2019 Q2 | 17.41 Million SEK | -21.32% |
| 2018 Q3 | 30.18 Million SEK | -10.0% |
| 2018 FY | 25.97 Million SEK | 125.17% |
| 2018 Q2 | 33.53 Million SEK | -18.07% |
| 2018 Q1 | 40.93 Million SEK | 254.85% |
| 2018 Q4 | 25.97 Million SEK | -13.95% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q4 | 11.53 Million SEK | 0.0% |
| 2017 FY | 11.53 Million SEK | 315.68% |
| 2016 FY | 2.77 Million SEK | 62.66% |
| 2016 Q4 | 2.77 Million SEK | 0.0% |
| 2015 FY | 1.7 Million SEK | 2.04% |
| 2014 FY | 1.67 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 92.115% |
| Ziccum AB (publ) | 14.97 Million SEK | 37.617% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | 53.396% |
| BioArctic AB (publ) | 1.18 Billion SEK | 99.213% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 85.027% |
| Mendus AB (publ) | 755.95 Million SEK | 98.764% |
| Genovis AB (publ.) | 288.85 Million SEK | 96.767% |
| Intervacc AB (publ) | 259.61 Million SEK | 96.402% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | 77.74% |
| Active Biotech AB (publ) | 44 Million SEK | 78.773% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 96.649% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 84.972% |
| Aptahem AB (publ) | 63.02 Million SEK | 85.18% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 98.118% |
| Kancera AB (publ) | 65.64 Million SEK | 85.772% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 97.342% |
| Saniona AB (publ) | 64.14 Million SEK | 85.439% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | 72.204% |
| Biovica International AB (publ) | 131.4 Million SEK | 92.892% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 82.372% |
| AcouSort AB (publ) | 34.51 Million SEK | 72.938% |
| Xintela AB (publ) | 18.39 Million SEK | 49.225% |
| Abliva AB (publ) | 87.49 Million SEK | 89.326% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 98.771% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 99.258% |
| OncoZenge AB (publ) | 20.34 Million SEK | 54.081% |
| Amniotics AB (publ) | 26.08 Million SEK | 64.195% |
| 2cureX AB (publ) | 16.62 Million SEK | 43.82% |
| CombiGene AB (publ) | 120.61 Million SEK | 92.256% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -53.694% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 99.509% |
| Camurus AB (publ) | 1.9 Billion SEK | 99.51% |
| Corline Biomedical AB | 100.1 Million SEK | 90.67% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 94.727% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 93.357% |
| I-Tech AB | 152.44 Million SEK | 93.873% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 99.083% |
| Cyxone AB (publ) | 43.65 Million SEK | 78.605% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 88.131% |
| Biosergen AB | 7.2 Million SEK | -29.704% |
| Cantargia AB (publ) | 223.71 Million SEK | 95.825% |
| NextCell Pharma AB | 81.28 Million SEK | 88.51% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 98.78% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | 69.045% |
| Nanologica AB (publ) | 77.42 Million SEK | 87.937% |
| SynAct Pharma AB | 228.01 Million SEK | 95.904% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | 65.101% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | 56.964% |
| LIDDS AB (publ) | 17.65 Million SEK | 47.097% |
| Lipum AB (publ) | 12.11 Million SEK | 22.874% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 99.333% |
| Alzinova AB (publ) | 123.18 Million SEK | 92.418% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 96.082% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -10.467% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 89.041% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | 37.185% |
| Simris Alg AB (publ) | 174.55 Million SEK | 94.649% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 95.697% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 98.571% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 89.273% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | 67.237% |